Safety and Tolerability: Clinical Trials

18 trials for Safety and Tolerability, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 2 unknown, 1 active not recruiting, 1 terminated. 18 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 118Completed 14, Unknown 2, Active not recruiting 1, Terminated 1

Follow Safety and Tolerability: new trials by email Literature Review of Safety and Tolerability trials Research Report on Safety and Tolerability

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants
MDI-2517, Placebo - Safety and Tolerability
Phase 1CompletedMDI Therapeutics, Inc.482024-05-172025-03-14
Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)
AK1967 (Procizumab), Placebo - Safety and Tolerability, Healthy Volunteers
Phase 1Completed4TEEN4 Pharmaceuticals GmbH242024-03-072026-02-27
A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers
Fenretinide, Placebo - Safety and Tolerability
Phase 1CompletedIsland Pharmaceuticals252023-11-222025-01-27
Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects
DF-003, Placebo - Healthy, Safety and Tolerability
Phase 1Active not recruitingShanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)962023-09-152026-06-03
A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570
ZP7570, Placebo - Safety and Tolerability
Phase 1TerminatedZealand Pharma842023-09-152025-04-25
Phase 1 Clinical Study of JMKX003142 Tablets
JMKX003142 will be administered orally, Placebo in Cohorts 1 to 7, Placebo in 3 Cohorts - Safety and Tolerability
Phase 1UnknownJemincare1062023-07-062023-10-17
Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects
JMKX003002 will be administered orally, Placebo in Cohorts 1 to 5, Placebo in 2 Cohorts - Safety and Tolerability
Phase 1UnknownJemincare802023-05-092023-06-18
Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers
YJ001 for Spray Use, Placebo of YJ001 for Spray Use - Safety and Tolerability
Phase 1CompletedYuejia Pharmaceuticals (USA), Inc.322022-08-152023-01-04
Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants
Experimental drug: ESK-001, Placebo - Safety and Tolerability
Phase 1CompletedAlumis Inc492022-05-122023-05-09
A Phase I Pharmacokinetics Study for KT07 Capsule
Low dose KT07, High dose KT07, Low dose Placebo - Healthy Adult Subjects, Pharmacokinetics
Phase 1CompletedYiling Pharmaceutical Inc.262022-01-072022-10-17
Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin
Sevuparin - Safety and Tolerability
Phase 1CompletedModus Therapeutics AB242019-02-062019-07-16
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
GB1211, Placebo - Safety and Tolerability
Phase 1CompletedGalecto Biotech AB782019-01-142021-03-17
Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers
GT-002, Placebo oral capsule - Safety and Tolerability
Phase 1CompletedGabather AB322018-12-172020-02-05
DP13 SAD & MAD in Healthy Male Subjects
DP13, placebo - Safety and Tolerability
Phase 1CompletedDamian Pharma AG482017-03-062018-04-17
Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers
K-312, Placebo - Safety and Tolerability
Phase 1CompletedKowa Research Institute, Inc.2013-05-012013-12-31
Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin
Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days - Safety and Tolerability
Phase 1CompletedMerLion Pharmaceuticals GmbH182012-01-012017-02-20
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
AZD5363 - Advanced Solid Malignancy, Safety and Tolerability
Phase 1CompletedAstraZeneca2852010-12-012025-06-29
Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects
ACT-128800, Placebo - Safety and Tolerability
Phase 1CompletedActelion162010-04-012014-01-08

Narrower conditions

Breast Neoplasms (1)  ·  Endometrial Neoplasms (1)  ·  Hereditary Sensory and Autonomic Neuropathies (1)  ·  Liver Cirrhosis (1)  ·  Non-alcoholic Fatty Liver Disease (1)  ·  Obesity (1)  ·  Ovarian Neoplasms (1)  ·  Overweight (1)  ·  Uterine Cervical Neoplasms (1)

Broader conditions

Pathological Conditions, Signs and Symptoms (2)  ·  Adnexal Diseases (1)  ·  Body Weight (1)  ·  Breast Diseases (1)  ·  Congenital Abnormalities (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Digestive System Diseases (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Fatty Liver (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Fibrosis (1)  ·  Genetic Diseases, Inborn (1)  ·  Genital Diseases (1)

Interventions

Fenretinide (1)  ·  Hypromellose Derivatives (1)  ·  Tablets (1)  ·  capivasertib (1)  ·  finafloxacin (1)  ·  ponesimod (1)  ·  procizumab (1)  ·  sevuparin (1)

Sponsors

Jemincare (2)  ·  4TEEN4 Pharmaceuticals GmbH (1)  ·  Actelion (1)  ·  Alumis Inc (1)  ·  AstraZeneca (1)  ·  Damian Pharma AG (1)  ·  Gabather AB (1)  ·  Galecto Biotech AB (1)  ·  Island Pharmaceuticals (1)  ·  Kowa Research Institute, Inc. (1)  ·  MDI Therapeutics, Inc. (1)  ·  MerLion Pharmaceuticals GmbH (1)  ·  Modus Therapeutics AB (1)  ·  Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) (1)  ·  Yiling Pharmaceutical Inc. (1)

Countries

United States (9)  ·  United Kingdom (4)  ·  China (2)  ·  Netherlands (2)  ·  Australia (1)  ·  Canada (1)  ·  Denmark (1)  ·  Finland (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Japan (1)  ·  Singapore (1)  ·  Spain (1)

Top investigators

Ashley Brooks, MBChB (1)  ·  Christopher Argent, MD (1)  ·  Darren Wilbraham, MBBS, DCPSA (1)  ·  David Wyatt, MD (1)  ·  Dr Ashley Brooks, MBChB (1)  ·  Dr Bertil Lindmark MD PHD, Chief Medical Officer (1)  ·  Gaia Schiavon, MSD (1)  ·  Javid Ghandehari, MD (1)  ·  Jing Zhang (1)  ·  Mark Bradley (1)  ·  Mark H. Gottfried, MD (1)  ·  Nan Zhang, PhD (1)  ·  Udai Banerji, MD, PhD (1)  ·  Ulrike Hoevelmann, MD (1)

Results publications

PMID 29066505, PMID 32312891, PMID 33863913, PMID 34250397, PMID 36914591, PMID 36914828, PMID 42166148

NIH funding

2018 (1)